See more : Dycom Industries, Inc. (DY) Income Statement Analysis – Financial Results
Complete financial analysis of Creso Pharma Limited (COPHF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Creso Pharma Limited, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Ordina N.V. (ORDI.AS) Income Statement Analysis – Financial Results
- Lever Style Corporation (1346.HK) Income Statement Analysis – Financial Results
- PHP Ventures Acquisition Corp. (PPHPU) Income Statement Analysis – Financial Results
- Brookfield Asset Management Inc (BXDIF) Income Statement Analysis – Financial Results
- Owens Corning (OC) Income Statement Analysis – Financial Results
Creso Pharma Limited (COPHF)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.cresopharma.com
About Creso Pharma Limited
Creso Pharma Limited develops, registers, and commercializes pharmaceutical-grade cannabis, and hemp-based nutraceutical products and treatments for human and animal health in Europe, the Middle East, North America, and the Asia Pacific. The company develops and commercializes therapeutic products; and cultivates, processes, and sells cannabis products, as well as supplies cannabis retail products. Its products include anibidiol, a complementary feed product for companion animals; cannaQIX, a nutraceutical product containing hemp oil extract, and vitamins and zinc that reduces stress and supports psychological and nervous functions; and topical and skin care products, which include cannaDOL, a CBD-based topical gel associated with a mixture of cooling and warming essential oils. Creso Pharma Limited was incorporated in 2015 and is headquartered in Nedlands, Australia.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 18.92M | 8.69M | 6.22M | 2.45M | 3.63M | 578.22K | 243.80K | 8.02K |
| Cost of Revenue | 16.59M | 8.40M | 6.62M | 6.33M | 1.50M | 353.57K | 437.70K | 32.83K |
| Gross Profit | 2.34M | 287.00K | -400.61K | -3.88M | 2.13M | 224.66K | -193.90K | -24.81K |
| Gross Profit Ratio | 12.34% | 3.30% | -6.44% | -158.61% | 58.62% | 38.85% | -79.53% | -309.22% |
| Research & Development | 0.00 | 0.00 | 0.00 | 344.99K | 286.03K | 286.54K | 788.62K | 488.98K |
| General & Administrative | 5.26M | 6.21M | 4.35M | 3.26M | 5.64M | 10.84M | 5.20M | 2.40M |
| Selling & Marketing | 794.00K | 1.68M | 5.84M | 986.18K | 698.00K | 1.23M | 1.83M | 238.23K |
| SG&A | 6.06M | 7.90M | 10.19M | 4.25M | 6.34M | 12.07M | 7.02M | 2.64M |
| Other Expenses | -3.72M | 11.58M | 17.76M | 5.89M | 5.68M | 62.96K | -56.03K | -26.71K |
| Operating Expenses | 2.34M | 19.48M | 27.95M | 10.49M | 12.30M | 16.42M | 13.85M | 4.16M |
| Cost & Expenses | 18.92M | 27.88M | 34.57M | 16.82M | 13.80M | 15.32M | 14.29M | 4.19M |
| Interest Income | 679.00K | 84.00K | 1.00 | 317.00 | 57.09K | 144.04K | 98.45K | 6.50K |
| Interest Expense | 9.69M | 692.00K | 1.71M | 9.27M | 2.09M | 432.22K | 0.00 | 36.75K |
| Depreciation & Amortization | 675.00K | 1.95M | 266.15K | 352.43K | 401.67K | 38.72K | 6.64K | 1.32K |
| EBITDA | -25.16M | -17.62M | -28.06M | -16.49M | -9.81M | -15.95M | -12.96M | -4.20M |
| EBITDA Ratio | -132.96% | -202.76% | -451.22% | -673.55% | -270.44% | -2,758.27% | -5,317.38% | -52,374.28% |
| Operating Income | -16.68M | -19.57M | -28.32M | -16.84M | -10.21M | -15.99M | -12.97M | -4.20M |
| Operating Income Ratio | -88.16% | -225.19% | -455.50% | -687.95% | -281.51% | -2,764.97% | -5,320.10% | -52,390.71% |
| Total Other Income/Expenses | -18.84M | -13.21M | -1.71M | -13.94M | -5.13M | -858.05K | -2.11M | -381.46K |
| Income Before Tax | -35.52M | -32.78M | -30.03M | -30.78M | -15.34M | -16.85M | -15.08M | -4.58M |
| Income Before Tax Ratio | -187.74% | -377.26% | -482.94% | -1,257.46% | -423.00% | -2,913.36% | -6,183.84% | -57,145.84% |
| Income Tax Expense | -3.00K | 2.00K | 1.73M | 6.80M | 1.71M | 336.18K | 975.65K | 10.04K |
| Net Income | -52.45M | -32.78M | -31.77M | -37.58M | -17.05M | -16.76M | -15.08M | -4.58M |
| Net Income Ratio | -277.18% | -377.28% | -510.84% | -1,535.17% | -470.25% | -2,897.86% | -6,183.84% | -57,145.84% |
| EPS | 0.00 | -0.02 | -0.03 | -0.10 | -0.12 | -0.15 | -0.18 | -0.14 |
| EPS Diluted | 0.00 | -0.02 | -0.03 | -0.10 | -0.12 | -0.15 | -0.18 | -0.14 |
| Weighted Avg Shares Out | 0.00 | 1.46B | 1.11B | 370.84M | 143.78M | 112.55M | 83.14M | 31.79M |
| Weighted Avg Shares Out (Dil) | 0.00 | 1.46B | 1.11B | 370.84M | 143.78M | 112.55M | 83.14M | 31.79M |
Melodiol Global Health Stock Scheduled to Reverse Split on Wednesday, June 5th (OTCMKTS:COPHF)
Shares of Melodiol Global Health Limited (OTCMKTS:COPHF – Free Report) are set to reverse split before the market opens on Wednesday, June 5th. The 1-30 reverse split was announced on Wednesday, June 5th. The number of shares owned by shareholders...
Cannabis stocks slump on SAFE Banking Act Senate hearing and mixed quarterly earnings
The Secure and Fair Enforcement (SAFE) Banking Act made headlines again this week as it was the focus of a Senate committee hearing on marijuana banking challenges. Typically any progress on this game-changing legislation for US cannabis businesses is welcomed by investors, sending...
Creso Pharma psychedelics subsidiary Halucenex Life Sciences broadens scope ahead of Phase 2 clinical trials
Creso Pharma Ltd (ASX:CPH, OTCQB:COPHF) (Creso Pharma Ltd (ASX:CPH, OTCQB:COPHF), Creso Pharma Ltd (ASX:CPH, OTCQB:COPHF)) subsidiary Halucenex Life Sciences Inc will expand the scope of Phase 2 clinical trials assessing the efficacy of psilocybin on treatment-resistant Post Traumatic Stress Disorder (PTSD)....
Creso Pharma subsidiary on official list to provide psilocybin to Canadian doctors
Creso Pharma Ltd (ASX:CPH, OTCQB:COPHF)'s wholly-owned, Canadian-based psychedelics subsidiary Halucenex Life Sciences Inc. has been included on a list of companies that can provide psychedelic compounds to researchers and patients under the SAP.
Australian Creso Pharma To Enter US CBD Market Via $21M Acquisition Of Sierra Sage Herbs
Cannabis company Creso Pharma Limited (ASX: CPH) (OTC: COPHF) (FRA:1X8) is entering the US CBD market, following a purchase agreement to acquire Colorado-based consumer packaged goods company, Sierra Sage Herbs, LLC. Under the agreement and subject to shareholder approval, Creso...
Creso Pharma pushes into US CBD market with revenue-generating acquisition
Creso Pharma Ltd (ASX:CPH, OTCQB:COPHF) has entered the US CBD market. The company has executed a Membership Interest Purchase Agreement to acquire Colorado-based consumer packaged goods company, Sierra Sage Herbs, LLC (SSH).
Creso Pharma psychedelics subsidiary Halucenex lodges CTA to test efficacy of psilocybin on treatment-resistant PTSD
Creso Pharma Ltd (ASX:CPH, OTCQB:COPHF) psychedelics subsidiary Halucenex Life Sciences Inc has lodged a Clinical Trial Authorisation (CTA) with Health Canada for a planned phase II clinical trial to test the efficacy of psilocybin on treatment-resistant Post Traumatic Stress Disorder (PTSD). The proposed...
Creso Pharma has eye on North America with new crop of cannabis-credentialled executives
Creso Pharma Ltd (ASX:CPH, OTCQB:COPHF) has launched the next stage of its growth strategy, appointing executives with strong backgrounds in the lucrative cannabis market. In a push to strengthen its executive team, CPH has appointed William Lay as CEO and managing...
Creso Pharma subsidiary Halucenex invited to become Special Access Program drug supplier in Canada
Creso Pharma Ltd (ASX:CPH, OTCQB:COPHF) subsidiary Halucenex Life Sciences Inc has been invited by Health Canada to become a potential supplier of psychedelics like psilocybin under the new Special Access Program (SAP) in Canada, unlocking potential revenue-generating opportunities. The SAP announced on...
Creso Pharma on-track for quarter-on-quarter revenue growth as Mernova records strong cannabis sales
Creso Pharma Ltd (ASX:CPH, OTCQB:COPHF)'s wholly-owned, Canadian subsidiary Mernova Medicinal Inc. has generated A$666,042 (C$612,734) in revenue during the current quarter, adding to the total of A$3,159,141 (C$2,979,797) to the year to date in divisional revenue.
Source: https://incomestatements.info
Category: Stock Reports